ДИФФЕРЕНЦИРОВАННЫЙ ПОДХОД К ЛЕЧЕНИЮ СИМПТОМОВ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ ПРИ ДОБРОКАЧЕСТВЕННОЙ ГИПЕРПЛАЗИИ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
- Авторы: Пушкарь ДЮ1, Бормотин АВ1, Pushkar DY.1
-
Учреждения:
- Выпуск: № 16 (2009)
- Страницы: 12-22
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/278071
- ID: 278071
Цитировать
Полный текст
Аннотация
Рассматриваются современные подходы к лечению доброкачественной гиперплазии предстательной железы (ДГПЖ). Представлены данные об этиологии, клинике и диагностике ДГПЖ. Обсуждаются возможности применения при ДГПЖ альфа1-адреноблокаторов и ингибиторов 5альфа-редуктазы. Обосновываются методы комбинированной терапии ДГПЖ с использованием альфа1-адреноблокаторов (короткий курс) и ингибиторов 5альфа-редуктазы, а также альфа1-адреноблокаторов в сочетании с антихолинергическими препаратами у больных ДГПЖ с симптомами гиперактивного мочевого пузыря. Значительное место уделено лечению острой задержки мочи.
Список литературы
- Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984;132(3):474-79.
- Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1c-adrenoreceptor antagonist: a randomized, controlled trial in a patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 1995;76(3):325-36.
- Evans HS, Moller H. Resent trends in prostate cancer incidence and mortality in Southeast England. Eur Urol 2003;43(4):337-41.
- Lanes SF, Sulsky S, Walker AM, et al. A cost density analysis of benign prostatic hyperplasia. Clin Ther 1996;18(5):993-1004.
- Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughan ED et al. Campbell's Urology, 8th ed. Philadelphia, PA: WB Saunders Co 2002:1297-336.
- Labreque J, Randolph R, Davis R. Benign prostatic hyperplasia: an overview for pharmacists. Am J Manag Care 1999;5:661-69.
- Kuritzky L. Benign prostatic hyperplasia. Compr Ther 1998;24:130-36.
- McNeal JG. The prostate gland: morphology and pathobiology. Monogr Urol 1983;4:3-33.
- Jepsen JV, Bruskewitz RC. Clinical manifestation and indications for treatment. In: Lepor H, ed. Prostatic Diseases. Philadelphia, PA: WB Saunders Co 2000:123-42.
- Isaacs J, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1987;2(Suppl.):33-50.
- Bosch JL, Hop WC, Kirkels WJ, et al. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology 1995;46(3 Suppl. A):34-40.
- Denis L, McConnell J, Yoshida O. The evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction. In: Denis L, Griffiths K, Khoury S, editors. Fours International Consultation on Benign Prostatic Hyperplasia (BPH). Paris: SCI 1998:669-84.
- Lepor H. Pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. Rev in Urol 2004;6(Suppl. 9):3-10.
- Roehrborn CG, Girman CJ, Rhodes T, et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology 1997;49:548-57.
- Bates TS, Reynard JM, Peters TJ, et al. Determination of prostate volume with transrectal ultrasound: a study of intraobserver and interobserver variation. J Urol 1996;155:1299-300.
- Marks LS, Linton HJ, Gasior CL, et al. BPSA is a potential serum marker for benign prostatic hyperplasia (BPH). J Urol 2001;165:266(Abstract).
- Barry MJ, Flower FJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549-57.
- Tsang KK, Garraway WM. Impact of benign prostatic hyperplasia on general well-been of men. Prostate 1993;23(1):1-7.
- Kawakami J, Nickel JC. Acute urinary retention and surgery for benign prostatic hyperplasia: the patient's perspective. Can J Urol 1999;6(3):819-22.
- American Urological Association. AUA guideline on the management of benign prostatic hyperplasia. 2003. Available from URL: http://www.auanet.org/timssnet/products/guidelines/bph_ management.com.
- Пытель Ю.А., Винаров А.З. Этиология и патогенез гиперплазии предстательной железы. В кн. Доброкачественная гиперплазия предстательной железы / Под ред. Н.А. Лопаткина. М., 1997. С. 19-32.
- Лоран О.Б., Вишневский Е.Л., Вишневский А.Е. Лечение расстройств мочеиспускания у больных доброкачественной гиперплазией простаты a-адреноблокаторами. Монография. М., 1998.
- Kuritzky L. Role of primary care clinicians in the diagnosis and treatment of LUTS and BPH. Rev in Urol 2004;6(Suppl. 9):53-59.
- Michel MC, Flannery MT, Narayan P. Worldwide experience with alfuzosin and tamsulosin. Urology 2001;58(4):508-16.
- Akduman B, Grawford ED. Terazosin, doxazosin and prazosin: current clinical experience.
- Brawer MK, Adams G, Epstein H. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. Arch Farm Med 1993;2(9):929-35.
- Lepor H, Auerbach S, Puras-Baez A, et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992;148(5):1467-74.
- Fawzy A, Braun K, Lewis GP, et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995;154(1):105-09.
- Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of the double-blind, placebo-controlled studies. Urology 1996;48(3):406-15.
- Djavan B, Marberger M. A meta-analysis of the efficacy and tolerability of alpha 1-adrenoreceptor antagonist in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1-13.
- Buzelin JM, Delauche-Cavallier MC, Roth S, et al. Clinical uroselectivity: Evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br J Urol 1997;79:898-906.
- Сивков А.В. Медикаментозная терапия доброкачественной гиперплазии предстательной железы. Доброкачественная гиперплазия предстательной железы / Под ред. Лопаткина Н.А. М., 1999. С. 91-116.
- Chapple C. Selective 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 1996;29:129-44.
- Пушкарь Д.Ю., Лоран О.Б., Раснер П.И. Терапия альфа-адреноблокаторами - метод выбора в лечении обструктивного мочеиспускания у мужчин и женщин // Фарматека 2002. №.10(61). С. 35-40.
- Choong S, Emberton M. Acute urinary retention. BJU International 2000;85:186-201.
- Marberger MJ, Andersen JТ, Nickel JС, et al. Prostate Volume and Serum Prostate-Specific Antigen as Predictors of Acute Urinary Retention. European Urology 2000;38:563-68.
- Manikandan R, Srirangam SJ, O'Reilly PH, et al. Management of acute urinary retention secondary to benign prostatic hyperplasia in the UK: a national survey. BJU Int 2004;93(1):84-88.
- McNeill SA. Does acute urinary retention respond to alpha-blockers alone? Eur Urol 2001;39(Suppl. 6):7-12.
- Choong S, Emberton M. Acute urinary retention. BJU International 2000;85:186-201.
- McNeill SA. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction. Eur Urol 2004;45(3):325-32.
- Перепанова Т.С., Камалов А.А., Синюхин В.Н. и др. Урология 2001. №2. С. 16-18.
- Kumar V, Marr C, Bhuvangiri A, et al. A prospective study of conservatively managed acute urinary retention: prostate size matters. BJU Int 2000;86(7):816-19.
- Пушкарь Д.Ю., Раснер П.И. Опыт консервативного лечения острой задержки мочи у больных доброкачественной гиперплазией предстательной железы одновременным назначением двух уроселективных альфа-адреноблокаторов - альфузозина и тамсулозина // Фарматека. 2006. № 15(130). С. 48-54.
- McConnell JD. Prostatic grows: new insights into hormonal regulation. Br J Urol 1995;76(Suppl. 1):5-10.
- Carson C, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003;61(Suppl. 1):2-7.
- Walsh PC, Madden JD, Harrod M. Familial incomplete male pseudohermaphroditism, type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med. 1974;291:944-9.
- Schalken JA. The androgen cascade in ageing men: blessing or curse? Eur Urol 2003;(Suppl. 2):8-12.
- Coffey DS, Shimazaki J, Williams-Ashman HG. Polymerization of deoxyribonucleotides in relation to androgen induced prostatic grows. Arch Biochem Biophys 1968;124(1):184-98.
- Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984;5(5):545-57.
- Marks LS, Partin AW, Dorey FJ, et al. Long-term effects of finasteride on prostate tissue composition. Urology 1999;53(3):574-80.
- Luo J, Dunn TA, Ewing CM, et al. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implication for finasteride therapy of prostate carcinoma. Prostate 2003;57(2):134-39.
- Bruchovsky N, Sadar MD, Akakura K, et al. Characterization of 5 alpha-reductase gene expression in stroma and epithelium of human prostate. J Steroid Biochem Mol Biol 1996;59:397-404.
- Silver RI, Wiley EJ, Davis DL, et al. Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease. J Urol 1994;152:433-37.
- Gormley GJ, Stoner E, Rittmaster RS, et al. Effects of finasteride (MK-906), a 5α-reductase inhibitor, on circulating androgen in male volunteers. J Clin Endocrinol Metab 1990;70:1136-41.
- Rittmaster RS, Stoner E, Thompson DL, et al. Effects of MK-906, a specific 5α-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl 1989;10:259-62.
- Gormley GJ, Stoner E, Bruskewitz RS, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Eng J Med 1992;327:1185-91.
- Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434-41.
- Hagerty JA, Ginsberg PC, Metro MJ, et al. A prospective, comparative study of the onset of symptomatic benefit of dutasteride versus finasteride in men with benign prostatic hyperplasia in clinical practice. J Urol 2004;171:356.
- Roehrborn CG. The clinical benefits of dutasteride treatment for LUTS and BPH. Rev in Urol 2004;6(Suppl. 9):22-30.
- Debruyne F, et al. Efficacy and Safety of Long-TermTreatment with the Dual 5a-Reductase Inhibitor Dutasteride inMenwith Symptomatic Benign Prostatic Hyperplasia. Eur Urol 2004;46:488-95.
- Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Eng J Med 2003;349:215-24.
- Marks LS. Treatment of men with minimally symptomatic benign prostatic hyperplasia-pro: the argument in favor. Urology 2003;62:781-83.
- Корниенко В.И. Эффективность медикаментозной терапии больных доброкачественной гиперплазией предстательной железы Автореф. дисс. канд. мед. наук. СПб., 1997.
- Djavan B, Barkin J. Novel therapeutic strategies for managing BPH progression. Eur Urol 2003;(Suppl. 2):20-26.
- McConnell JD, For the MTOPS Research Group. The long term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Eng J Med 2003;349:2385-96.
- Barkin J, Guimaraes M, Jacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 2003;44:461-66.
- Brading AF. A myogenic basis for the overactive bladder. Urology 1997;50(Suppl.):57-73.
- Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000;6(Suppl. 11):S580-90.
- Andersson KE. Treatment of overactive bladder: other drug mechanisms. Urology 2002;55(5A Suppl.):51-7.
- Brading AF, Turner WH. The instable bladder: towards a common mechanism. Br J Urol 1994;73(1):3-8.
- Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006;49(4):651-59.
- Rovner ES, Wein AJK. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol 2002;41(1):6-14.
- Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging 2005;22(12):1013-28.
- Siddiqui MA, Perry CM, Scott LJ. Oxybutynin extended-release: a review of its use in the management of overactive bladder. Drugs 2004;64(8):885-912.
- Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003;169(6):2253-56.
- http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2420&mid=1085056570&magid=180
Дополнительные файлы
![](/img/style/loading.gif)